Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-25-001906
Filing Date
2025-03-11
Accepted
2025-03-11 19:22:10
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11330
2 d11622438_ex99-a.htm EX-99 5020
3 d11622438_ex99-b.htm EX-99 661
  Complete submission text file 0000919574-25-001906.txt   18960
Mailing Address 17383 SUNSET AVENUE SUITE A250 PACIFIC PALISADES CA 90272
Business Address 17383 SUNSET AVENUE SUITE A250 PACIFIC PALISADES CA 90272 424-473-8055
Aadi Bioscience, Inc. (Subject) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-83932 | Film No.: 25729521
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022
Business Address 540 MADISON AVENUE 7TH FLOOR NEW YORK NY 10022 2127025204
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by) CIK: 0001569064 (see all company filings)

EIN.: 453704500 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G